The firefighters had elevated standardized incidence ratios for prostate cancer and melanoma.
A retrospective study evaluated the effect of 5% imiquimod prior to Mohs surgery in patients with basal cell carcinoma.
Bacteroides intestinalis and Intestinibacter bartlettii were significantly enriched in patients who experienced severe toxicity.
The application is supported by data from the phase 2 IMCgp100-202 trial that assessed tebentafusp in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
How significant is the racial disparity in treating patients with skin cancer? Studies in recent years that suggest a troubling difference in the diagnosis and treatment some patients receive. We explore the significant impact this has on patient prognosis.
Prior therapy linked to lower objective response rate to adoptive cell transfer with tumor-infiltrating lymphocytes compared with no prior therapy.
Female patients showed an enhanced rate of dermatologic adverse events with immune checkpoint inhibitor therapy for metastatic melanoma.
Beta-HPV detected in skin swabs may predict cuSCC risk, but no link seen for serologic evidence of past beta-HPV infection.
Authors recommend that dermatologists perform a total-body skin examination even when a patient is referred for a suspicious lesion.
Researchers studied a total of 1903 cases of pediatric melanoma and patients were 54.4% female, the mean age was 12.4 years, and 89.8% were White.
Remetinostat produced a complete response in 17 of 33 tumors.
Odds for melanoma detection highest for presence of white structures, pseudopods, irregular pigmentation, blue-white veil, and peppering.
Response endpoints were not strongly correlated with overall survival at the trial level.
The test can accurately detect cancer and predict where it is located, according to researchers.
Combination ipilimumab and nivolumab reduced the risk of death by 56% when compared with fotemustine monotherapy.
Phase 2 trial results supported the approval of cemiplimab for this patient group.
More than half of patients responded, and responses deepened over time.
Immune-related adverse events were associated with improved survival outcomes.
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response.